Development of a Series of (1-Benzyl-3-(6-Methoxypyrimidin-3-Yl)-5-(Trifluoromethoxy)-1h-Indol-2-Yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists With in Vivo Utility and Activity Against Γ-Thrombin

Journal of Medicinal Chemistry - United States
doi 10.1021/acs.jmedchem.6b00928

Related search